Clinical pathological analysis shows that low ARID1A mRNA expression in breast cancer is associated with advanced tumors, increased P53(+) percentage, and high Ki-67 expression, and 78% of triple-negative breast cancers exhibit low ARID1A expression [39]. This evidence concerns the gene ARID1A and breast carcinoma.